Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Phospho-NACA (Ser43) Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA564693
Description
Phospho-NACA (Ser43) Polyclonal Antibody detects endogenous levels of NACA only when phosphorylated at Ser43.
NACA prevents inappropriate targeting of non-secretory polypeptides to the endoplasmic reticulum (ER). It binds to nascent polypeptide chains as they emerge from the ribosome and blocks their interaction with the signal recognition particle (SRP), which normally targets nascent secretory peptides to the ER. NACA also reduces the inherent affinity of ribosomes for protein translocation sites in the ER membrane (M sites), and may act as a specific coactivator for JUN, binding to DNA and stabilizing the interaction of JUN homodimers with target gene promoters.
Specifications
Phospho-NACA (Ser43) | |
Polyclonal | |
Unconjugated | |
NACA | |
AL022831; AL024382; Alpha-NAC; Alpha-NAC, muscle-specific form; alpha-NAC/1.9.2; Gm1878; Hom s 2; HSD48; mKIAA0363; NACA; NACA1; NAC-alpha; nascent polypeptide-associated complex alpha polypeptide; nascent polypeptide-associated complex alpha subunit; nascent polypeptide-associated complex subunit alpha; Nascent polypeptide-associated complex subunit alpha, muscle-specific form; nascent-polypeptide-associated complex alpha polypeptide; skNAC | |
Rabbit | |
Affinity Chromatography | |
RUO | |
17938, 288770, 4666 | |
-20°C | |
Liquid |
Immunohistochemistry, Immunohistochemistry (Paraffin), Western Blot | |
1 mg/mL | |
PBS with 30% glycerol and 0.02% sodium azide; pH 7.3 | |
E9PAV3, P70670, Q13765, Q60817 | |
NACA | |
A synthesized peptide derived from human NACA (Phospho-Ser43). | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction